Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00431301 · ClinicalTrials.gov registry record
Risk Factors for Progressive Supranuclear Palsy (PSP)
A clinical trial, sponsored by University of Louisville.
- Completed
- Registry status
- 942
- Enrollment target
NCT00431301: Completed study, sponsored by University of Louisville.
NCT00431301 is a clinical trial that has completed, run by University of Louisville. The registered enrollment target is 942 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00431301 has completed, sponsored by University of Louisville.
- COMPLETED
- Registry status
- 942 participants
- Enrollment target
Study Summary
Progressive supranuclear palsy (PSP) is the most common atypical parkinsonian movement disorder. This study will determine the role of specific genetic, occupational and environmental components in the development of PSP by evaluating patients with this disorder and age and gender matched controls.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 942 participants |
| Start Date | 2006-08 |
| Est. Completion | 2013-06 |
What the finished NCT00431301 record still lists
NCT00431301 is an observational study that tracks outcomes without assigning an intervention. The registered 942 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT00431301 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00431301 about?
NCT00431301 is a clinical study titled "Risk Factors for Progressive Supranuclear Palsy (PSP)". Progressive supranuclear palsy (PSP) is the most common atypical parkinsonian movement disorder. This study will determine the role of specific genetic, occupational and environmental components in the development of PSP by evaluating patients with this disorder and age and gender matched controls.
What is the current status of trial NCT00431301?
This trial is currently completed. The enrollment target is 942 participants. The study started on 2006-08. Estimated completion is 2013-06.
Who is sponsoring clinical trial NCT00431301?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06808334 · 942 participants
CLAiR Pivotal Study
- NCT07190209 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- NCT07190222 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- NCT05020236 · 944 participants · Phase 3
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia